Emma Banwell1, Bennis Pavisian2, Liesly Lee3, Anthony Feinstein4. 1. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: 11ecb9@queensu.ca. 2. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: bennis.pavisian@sri.utoronto.ca. 3. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: liesly.lee@sunnybrook.ca. 4. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; University of Toronto, Toronto, Ontario, Canada. Electronic address: ant.feinstein@utoronto.ca.
Abstract
BACKGROUND: Canada has the highest incidence of MS worldwide. Anecdotal evidence reveals that people with MS smoke, ingest or vaporize cannabis for a multiplicity of reasons. With the legal situation in relation to use currently in flux, we undertook a study investigating patterns of use amongst people with MS and their attitudes towards the drug. METHODS: A consecutive sample of people with MS (n=246) attending a neurology (n=118) and a neuropsychiatry (n=107) clinic was enrolled and asked to complete a questionnaire containing demographic, disease and cannabis related variables. RESULTS: Of the 246 people approached, 225 (91.8%) agreed to participant. Attitude towards cannabis revealed that 122 (54.3%) participants approved of the drug while 75 (33.2%) were neutral. Legalization was endorsed by 98 (43.7%) participants, while 98 (43.7%) were in favour of legalization for medical use only. Current use was endorsed by 44 (19.5%) people with 125 (56.1%) reporting lifetime use. If cannabis were legal, 113 (50.2%) participants would use it. The most common symptoms for which cannabis was being used were: sleep (86%), pain (75%), anxiety (73%) and spasticity (68%). Participants attending the neuropsychiatry clinic were more likely to use cannabis for managing depression (χ2=4.99; p=0.03) and pain (χ2=3.85; p=0.05). CONCLUSION: There is a wide acceptance of cannabis within the MS patient community. One in five people currently use the drug for reasons that differ between neuropsychiatry and neurology clinics. Use could potentially more than double if the drug were legalized. Copyright Â
BACKGROUND: Canada has the highest incidence of MS worldwide. Anecdotal evidence reveals that people with MS smoke, ingest or vaporize cannabis for a multiplicity of reasons. With the legal situation in relation to use currently in flux, we undertook a study investigating patterns of use amongst people with MS and their attitudes towards the drug. METHODS: A consecutive sample of people with MS (n=246) attending a neurology (n=118) and a neuropsychiatry (n=107) clinic was enrolled and asked to complete a questionnaire containing demographic, disease and cannabis related variables. RESULTS: Of the 246 people approached, 225 (91.8%) agreed to participant. Attitude towards cannabis revealed that 122 (54.3%) participants approved of the drug while 75 (33.2%) were neutral. Legalization was endorsed by 98 (43.7%) participants, while 98 (43.7%) were in favour of legalization for medical use only. Current use was endorsed by 44 (19.5%) people with 125 (56.1%) reporting lifetime use. If cannabis were legal, 113 (50.2%) participants would use it. The most common symptoms for which cannabis was being used were: sleep (86%), pain (75%), anxiety (73%) and spasticity (68%). Participants attending the neuropsychiatry clinic were more likely to use cannabis for managing depression (χ2=4.99; p=0.03) and pain (χ2=3.85; p=0.05). CONCLUSION: There is a wide acceptance of cannabis within the MS patient community. One in five people currently use the drug for reasons that differ between neuropsychiatry and neurology clinics. Use could potentially more than double if the drug were legalized. Copyright Â
Authors: Sheila Gupta; Kelly Fellows; Bianca Weinstock-Guttman; Jesper Hagemeier; Robert Zivadinov; Murali Ramanathan Journal: Int J MS Care Date: 2019 Mar-Apr
Authors: Tiffany J Braley; Daniel Whibley; Kevin N Alschuler; Dawn M Ehde; Ronald D Chervin; Daniel J Clauw; David Williams; Anna L Kratz Journal: Mult Scler J Exp Transl Clin Date: 2020-09-22
Authors: Amber Salter; Robert J Fox; Gary Cutter; Ruth Ann Marrie; Kate E Nichol; Joshua R Steinerman; Karry M J Smith Journal: Int J MS Care Date: 2021-12-29
Authors: Marcin Ożarowski; Tomasz M Karpiński; Aleksandra Zielińska; Eliana B Souto; Karolina Wielgus Journal: Int J Mol Sci Date: 2021-04-21 Impact factor: 5.923